#Open journalism No news is bad news

Your contributions will help us continue to deliver the stories that are important to you

Support The Journal
Dublin: 6°C Monday 12 April 2021
Advertisement

French pharma company halts Covid-19 drug trial after 'inconclusive' clinical tests

The drug was being developed to treat serious cases of the disease.

Sanofi is one of many companies developing a vaccine.
Sanofi is one of many companies developing a vaccine.
Image: PA

FRENCH PHARMA GIANT Sanofi has said that international Phase 3 clinical tests of its Kevzara drug for serious Covid-19 cases had proved inconclusive and it was halting the trial.

The Phase 3 test – normally the last before official approval for use – “did not meet the primary or secondary evaluation criteria compared with a placebo, and in both cases, compared with established hospital care,” it said in a statement.

Sanofi said neither it nor its American partner in developing the drug, Regeneron, “envisage further clinical tests of Kevzara for the treatment of Covid-19.”

Although Kevzara “did not give us the results we were hoping for, we are proud of the work done by our team,” Sanofi global research head Dr John Reed said in the statement.

Since the outbreak of the coronavirus pandemic late last year in China, it has claimed more than 800,000 lives and caused huge economic damage, sparking a global race to find a vaccine and effective treatments.

Sanofi is one of many companies developing a vaccine but scientists are cautious in saying that at best, one may only be available by the end of this year for initial use.

#Open journalism No news is bad news Support The Journal

Your contributions will help us continue to deliver the stories that are important to you

Support us now

- © AFP 2020.

About the author:

AFP

Read next:

COMMENTS (19)

This is YOUR comments community. Stay civil, stay constructive, stay on topic. Please familiarise yourself with our comments policy here before taking part.
write a comment

    Leave a commentcancel